Donepezil for the Treatment of Mild to Moderate Alzheimer’s Disease in France: The Economic Implications

Publisher： Karger

E-ISSN： 1421-9824|17|1-2|5-13

ISSN： 1420-8008

Source： Dementia and Geriatric Cognitive Disorders, Vol.17, Iss.1-2, 2003-12, pp. : 5-13

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An Economic Evaluation of Donepezil in Mild to Moderate Alzheimer’s Disease: Results of a 1-Year, Double-Blind, Randomized Trial

By  

Dementia and Geriatric Cognitive Disorders, Vol. 15, Iss. 1, 2002-12 ,pp. : 44-54

Karger

Access to resources Recommend Favorite

Economic Evaluation of Donepezil Treatment for Alzheimer’s Disease in Japan

By  

Dementia and Geriatric Cognitive Disorders, Vol. 13, Iss. 1, 2001-12 ,pp. : 33-39

Karger

Access to resources Recommend Favorite

Economic Analysis of Galantamine, a Cholinesterase Inhibitor, in the Treatment of Patients with Mild to Moderate Alzheimer’s Disease in The Netherlands

By  

Dementia and Geriatric Cognitive Disorders, Vol. 14, Iss. 2, 2002-07 ,pp. : 84-89

Karger

Access to resources Recommend Favorite

Galantamine Prolonged-Release Formulation in the Treatment of Mild to Moderate Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 20, Iss. 2-3, 2005-08 ,pp. : 120-132

Karger

Access to resources Recommend Favorite

Effectiveness of Donepezil in Reducing Clinical Worsening in Patients with Mild-to-Moderate Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 28, Iss. 3, 2009-09 ,pp. : 244-251

Karger

Access to resources Recommend Favorite